GlassScriptPhysician profile
Maximilian E Garces
NPI 1588650436
$1,958.49
in general payments reported to CMS, 2019-2025
22 companies · $586 in 2025
The $586 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $97.31 · 2022: $191 · 2023: $326 · 2024: $263 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $294.94 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $290.89 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $257.02 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.63 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $145.50 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Sanofi-Aventis U.S. LLC | $107.46 | 2025 | |
| Abbott Laboratories | $84.00 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $82.52 | 2019-2020 | |
| Amarin Pharma, INC. | $73.10 | 2019-2022 | |
| Pfizer INC. | $72.44 | 2019-2025 | |
| Abbvie INC. | $72.17 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $65.26 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $56.21 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $41.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $33.92 | 2020-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rhythm Pharmaceuticals, INC. | $23.17 | 2025 | Imcivree |
| Allergan, INC. | $20.19 | 2020 | |
| Sanofi Pasteur INC. | $19.76 | 2019 | |
| Merck Sharp & Dohme LLC | $18.23 | 2022 | |
| Therapeuticsmd, INC. | $15.40 | 2019 | |
| Ibsa Pharma INC. | $14.18 | 2025 | Tirosint, Licart, Flector |
| Novartis Pharmaceuticals Corporation | $13.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximilian Garces listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.